⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for famitinib

Every month we try and update this database with for famitinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)NCT02356991
Non-Small Cell ...
Famitinib
Placebo
18 Years - 70 YearsJiangsu HengRui Medicine Co., Ltd.
Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid TumorNCT04346381
Solid Tumor
Camrelizumab
Famitinib
18 Years - 75 YearsJiangsu HengRui Medicine Co., Ltd.
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast CancerNCT05176080
Metastatic Brea...
Famitinib
SHR6390
Fulvestrant
18 Years - 75 YearsHenan Cancer Hospital
A Phase I Study of Famitinib Malate in Patients With Solid TumorNCT01762280
Advanced Solid ...
Famitinib Malat...
18 Years - 65 YearsJiangsu HengRui Medicine Co., Ltd.
A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid TumorsNCT04679038
Solid Tumor
SHR-1701
Famitinib
18 Years - Jiangsu HengRui Medicine Co., Ltd.
Cancer Genome Study Using Samples From Patients Treated on Clinical Trial SHR1020-SHR-1210-II-OSNCT03997747
Osteosarcoma
cytology specim...
12 Years - Peking University People's Hospital
A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic CholangiocarcinomaNCT04479904
Intrahepatic Ch...
Famitinib
18 Years - 75 YearsJiangsu HengRui Medicine Co., Ltd.
Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and CamrelizumabNCT03919539
Drug Resistance...
Biomarkers for ...
5hmc testing
12 Years - Peking University People's Hospital
A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine TumorNCT01994213
Gastroenteropan...
Famitinib
18 Years - 75 YearsJiangsu HengRui Medicine Co., Ltd.
Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid CarcinomaNCT04888429
Sarcomatoid Car...
Camrelizumab
Famitinib
18 Years - 75 YearsTongji Hospital
Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerNCT04355858
Breast Cancer
Metastatic Canc...
SHR7390
Famitinib
SHR3162
Pyrotinib
Capecitabine
SHR1210
Everolimus
Nab paclitaxel
SHR2554
SHR3680
SHR6390
SHR1701
SERD
AI
VEGFi
18 Years - 75 YearsFudan University
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast CancerNCT05176080
Metastatic Brea...
Famitinib
SHR6390
Fulvestrant
18 Years - 75 YearsHenan Cancer Hospital
A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid TumorsNCT04679038
Solid Tumor
SHR-1701
Famitinib
18 Years - Jiangsu HengRui Medicine Co., Ltd.
A Study of Famitinib in Patients With Advanced Colorectal CancerNCT01762293
Colorectal Canc...
Colorectal Canc...
Colorectal Canc...
Famitinib
placebo
18 Years - 70 YearsJiangsu HengRui Medicine Co., Ltd.
A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic CholangiocarcinomaNCT04479904
Intrahepatic Ch...
Famitinib
18 Years - 75 YearsJiangsu HengRui Medicine Co., Ltd.
Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerNCT04355858
Breast Cancer
Metastatic Canc...
SHR7390
Famitinib
SHR3162
Pyrotinib
Capecitabine
SHR1210
Everolimus
Nab paclitaxel
SHR2554
SHR3680
SHR6390
SHR1701
SERD
AI
VEGFi
18 Years - 75 YearsFudan University
Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerNCT04355858
Breast Cancer
Metastatic Canc...
SHR7390
Famitinib
SHR3162
Pyrotinib
Capecitabine
SHR1210
Everolimus
Nab paclitaxel
SHR2554
SHR3680
SHR6390
SHR1701
SERD
AI
VEGFi
18 Years - 75 YearsFudan University
Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma(FACT)NCT02390947
Colorectal Canc...
Colorectal Canc...
Famitinib
Placebo
18 Years - 75 YearsJiangsu HengRui Medicine Co., Ltd.
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast CancerNCT05176080
Metastatic Brea...
Famitinib
SHR6390
Fulvestrant
18 Years - 75 YearsHenan Cancer Hospital
A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.NCT04733417
Advanced Breast...
Metastatic Brea...
SHR6390
famitinib
18 Years - 75 YearsTianjin Medical University Cancer Institute and Hospital
A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic CholangiocarcinomaNCT04479904
Intrahepatic Ch...
Famitinib
18 Years - 75 YearsJiangsu HengRui Medicine Co., Ltd.
A Phase I Study of Famitinib Malate in Patients With Solid TumorNCT01762280
Advanced Solid ...
Famitinib Malat...
18 Years - 65 YearsJiangsu HengRui Medicine Co., Ltd.
Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and CamrelizumabNCT03919539
Drug Resistance...
Biomarkers for ...
5hmc testing
12 Years - Peking University People's Hospital
Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced OsteosarcomaNCT04044378
Effect of Drugs
Progression
Pediatric Cance...
Famitinib
Ifosfamide
Camrelizumab
12 Years - Peking University People's Hospital
A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.NCT04733417
Advanced Breast...
Metastatic Brea...
SHR6390
famitinib
18 Years - 75 YearsTianjin Medical University Cancer Institute and Hospital
SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaNCT05020925
Nasopharyngeal ...
SHR-1701
Famitinib
18 Years - 75 YearsJiangsu HengRui Medicine Co., Ltd.
A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid TumorsNCT04679038
Solid Tumor
SHR-1701
Famitinib
18 Years - Jiangsu HengRui Medicine Co., Ltd.
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological TumorsNCT03827837
Renal Cell Carc...
Urothelial Carc...
Cervical Cancer
Ovarian Cancer ...
Endometrial Can...
SHR-1210
Famitinib
18 Years - Jiangsu HengRui Medicine Co., Ltd.
A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine TumorNCT01994213
Gastroenteropan...
Famitinib
18 Years - 75 YearsJiangsu HengRui Medicine Co., Ltd.
Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid CarcinomaNCT04888429
Sarcomatoid Car...
Camrelizumab
Famitinib
18 Years - 75 YearsTongji Hospital
Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid TumorNCT04346381
Solid Tumor
Camrelizumab
Famitinib
18 Years - 75 YearsJiangsu HengRui Medicine Co., Ltd.
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: